Biocon faces regulatory heat as USFDA flags critical issues at its Bengaluru facility
In a significant development that has sent shockwaves through the biotechnology industry, Biocon Ltd. has come under fire from the U.S. Food and Drug Administration ... Read More
Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal
Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada's esteemed specialty pharmaceutical giant. This ... Read More
Biocon Generics acquires US facility for $7.7m, targets two billion tablet capacity
Biocon Limited, a global leader in the biopharmaceutical industry, has made a landmark announcement: its wholly-owned subsidiary, Biocon Generics Inc., has successfully acquired Eywa Pharma ... Read More
Biocon Biologics wraps up integration of former Viatris biosimilars business
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars business from Viatris in over 70 countries ... Read More
Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability of its biosimilar injection, HULIO (adalimumab-fkjp), in ... Read More
FDA rejects Biocon Biologics BLA for Insulin-R product
Biocon Limited, an Indian biopharma company, said that its subsidiary Biocon Biologics has been issued a complete response letter (CRL) from the US Food and ... Read More
Biocon Biologics wraps up $3.3bn acquisition of Viatris biosimilars unit
Biocon said that its subsidiary Biocon Biologics has wrapped up the previously announced $3.3 billion acquisition of the biosimilars business of US-based pharma company Viatris. ... Read More
Biocon partners with Zentiva for European marketing of Liraglutide
Biocon Limited has entered into a semi-exclusive partnership with Zentiva, a Czech pharma company for marketing its drug-device combination Liraglutide for the treatment and management ... Read More
Biocon Biologics signs licensing deal for two biosimilars with Yoshindo
Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo Inc. for commercializing a couple of its ... Read More
Biocon Q4FY22 results : Indian pharma firm net profit down by 6% to Rs 239cr
Biocon Q4FY22 results : Biocon Ltd has reported a net profit of INR 239 crores for the fourth quarter of the fiscal year 2022 (Q4FY22), ... Read More